ClinConnect ClinConnect Logo
Search / Trial NCT06536530

Benefits of Exergames on Neurocognitive Functions in Adults Suffering From Depression

Launched by MAP INSTITUTE · Jul 31, 2024

Trial Information

Current as of July 22, 2025

Not yet recruiting

Keywords

Cognition Neuropsychology Neuroplasticity Event Related Potentials Exergames Video Games

ClinConnect Summary

This clinical trial is exploring how "exergames," which are video games that combine physical activity and mental challenges, can help improve brain function and overall well-being in adults dealing with depression. The study aims to see if these fun and engaging games can boost cognitive abilities, improve coordination, and change brain activity in people aged 65 to 74 who have been diagnosed with moderate to severe depression.

To be eligible for this trial, participants must have a score of 28 or higher on a depression assessment called the Beck Depression Inventory, which indicates more significant symptoms of depression. They also need to understand the study and communicate effectively with the researchers. However, individuals with certain other mental health conditions, severe vision problems, or who cannot participate in the activities will not be included. If you join, you can expect to play exergames and participate in assessments to track any changes in your mood and mental abilities throughout the study.

Gender

ALL

Eligibility criteria

  • The inclusion and exclusion criteria for persons suffering from depression, will be validated by a professional (psychologist), through an interview and the use of reliable and valid psychological assessment tools.
  • Inclusion Criteria:
  • Using the Beck Depression Inventory-Second Edition (BDI-II), a scored considered for inclusion criteria where depression (≥ 28 points on BDI-II), confirmed by psychological interview.
  • A sufficient level of education to understand study procedures and be able to communicate with site personnel
  • Exclusion Criteria:
  • Participants suffering from depression with comorbidities (bipolar disorder, obsessive-compulsion disorder, neurological disorder, or traumatic brain injury) will be excluded.
  • \<20/60 vision with or without correction
  • Inability to complete the activities
  • Communication problems

About Map Institute

Map Institute is a leading clinical research organization dedicated to advancing medical science through innovative trials and research methodologies. With a focus on improving patient outcomes, the institute collaborates with healthcare professionals and institutions to develop and implement cutting-edge clinical studies across various therapeutic areas. Committed to ethical standards and regulatory compliance, Map Institute leverages its expertise to drive the discovery of new treatments, facilitate drug development, and contribute to the broader healthcare landscape. Through its rigorous approach and dedication to excellence, Map Institute aims to bridge the gap between research and real-world application, fostering a healthier future for patients globally.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported